Baminercept (BG 9924) 是一种抗淋巴毒素 β 受体 (LTβR) IgG 融合蛋白 (LTβR-Ig)。Baminercept 可选择性结合 LTβR 的配体 LTα/β 异三聚体及 LIGHT，阻断 LTβR 信号通路，抑制 CXCL13 等趋化因子表达。Baminercept 能够调节外周血 B 细胞和 T 细胞亚群，减少 IFN 诱导基因的转录，从而抑制淋巴组织中高内皮微静脉和网状结构的形成，影响免疫细胞迁移。Baminercept 可用于原发性干燥综合征 (pSS)、类风湿关节炎 (RA) 等自身免疫性疾病的研究。
| 生物活性 |
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA). |
|---|---|
| 分子量 |
93.76 kDa
|
| CAS号 |
909110-25-4
|
| 运输条件 |
Shipping with dry ice. |
| 储存方式 |
Powder : -20°C 3 years 4°C 2 years In solvent : -80°C 6 months -20°C 1 month |
纯度： 98%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet